Summary
Primary pulmonary hypertension (PPH) is a rare disease of unknown aetiology which typically results in right heart failure and death within several years of the onset of symptoms . While there is no cure for PPH, several pharmacological and surgical approaches to treatment have been developed over the past decade which have proved useful in a significant proportion of patients. In particular, vasodilator therapy may produce sustained haemodynamic and symptomatic improvement in up to approximately two-thirds of patients; in the remaining patients, vasodilators may either produce no benefit or result in deterioration.
The calcium channel blocking agents are the most widely used oral vasodilators; continuous intravenous infusions of epoprostenol (prostacyclin; iprostaglandin 12) have been used in some patients who are refractory to oral therapy, particularly as a bridge to transplantation. While combined heart-lung transplantation has been considered the surgicaljprocedure of choice for severepulmonary hypertension, single lung transplantation has been p~iforned successfully in a small number of patients, and may be the preferred approach in patients with reasonably preserved right heart function.
Signs and Symptoms
Primary pulmonary hypertension (PPH), a disease of unknown cause, is characterised by marked elevations in pulmonary artery pressure. This increased afterload to the right ventricle results in impaired right heart function, producing symptoms of exertional dyspnoea, fatigue, chest pain or syncope, and often results in right heart failure and death. A clinical diagnosis of PPH can be established only when other potential causes for pulmonary hypertension such as thromboembolic disease, parenchymal lung disease, congenital or valvular heart disease, and connective tissue diseases, have been ruled out. The prognosis of PPH is variable, but most patients with haemodynamic evidence of significant and sustained right ventricular dysfunction die within 3 years of diagnosis (Rich & Levy 1984; Rubin 1991) .
The pathological features of PPH range from mild intimal thickening and medial hypertrophy of the small muscular pulmonary arteries to intimal fibrosis and near complete obliteration of the vascular lumen with only small canaliculi remaining (plexiform lesions) [Wagenvoort & Wagenvoort 1970] . Pulmonary veno-occlusive disease, an uncommon form of PPH, is characterised pathologically by fibrosis and obstruction of the small pulmonary venules and veins , with secondary changes upstream in the arterial circuit. Pulmonary venoocclusive disease may be recognised clinically when a patient with pulmonary hypertension has radiographic evidence ofKerley B lines, but a normal pulmonary capillary wedge pressure during cardiac catheterisation. Since pharmacological treatment poses substantial risks i n patients with veno-occlusive disease (see section 2.5), it is important to recognise this entity .prior to embarking on a .treatment regimen.
There is neither a cure for PPH,nor ari approach to treatment that is uniformly accepted or successful. There are, however, a variety of therapeutic options which are available to the clinician responsible for the care of patients with this disease. This article reviews these treatment options Drugs 43 (l) 1992 and provides guidelines for the approach to management of PPH.
Treatment

Supplemental Oxygen Therapy
Alveolar hypoxia frequently complicates many forms of severe chronic lung disease and hypoxic pulmonary vasoconstriction contributes to the pulmonary hypertension of chronic respiratory illness . Alleviating arterial hypoxaemia with th~iuse of lowflow supplemental oxygen is an important component of therapy. In contrast, most patients with PPH do not manifest resting hypoxaemia and derive little haemodynamic benefit from supplemental oxygen therapy (Morgan et al. 1990 . However, some PPH patients will experience/~rterial oxygen desaturation with activity due to j ncreased oxygen extraction in the face of fixed oxygen delivery ; these patients may benefit from ambplatOry supplemental oxyg~n. Patients w~th seve~~right heart failure and resting hypoxaemia resulting from a markedly increased oxygen extraction, e~en at rest, should be treated with continuous oxyge~therapy. The goal of oxygen therapy is to maintain an arterial oxygen saturation above 90 to 92%. Patients with hypoxaemia resulting from a right-to-left shunt through a patent foramen ovale characteristically do notimprove their level of oxygenation to an appreciable degree with supplemental oxygen.
Cardiac Glycosides
The effects of digitalis on ventricular function are well known, and cardiac glycosides are widely used to treat patients with left ventricular failure . There is little evidence, however, that these drugs are useful in patients with isolated right ventricular dysfunction (Mathus et al. 1981) . Furthermore, the risk of digitalis toxicity may be enhanced if hypoxaemia and diuretic-induced hypokalaemia are also present (Green & Smith 1977) . Finally, cardiac glycosides have been demonstrated to directly increase tension in isolated pulmonary artery rings, an effect which may be mediated by a transmembrane Na"jCa+ exchange (Salvaterra et al. 1989 ).
Thus, cardiac glycosides should be used cautiously in patients with isolated right heart disease resulting from pulmonary hypertension. Some authors have advocated the use of digitalis concomitant with calcium channel blockers in patients with PPH in order to counteract the negative inotropic effects which may occur with the use of the latter (Rich & Brundage J987).
Diuretics
Diuretics can be quite useful in reducing increased intravascular volume which .occurs in patients with right heart failure; by reducing preload, right 'ventricular function may be improved. However, the right ventricle is highly dependent on preload, and great care should be given to avoid excessive diuresis in these patients since this can lead to a fall in cardiac output and compromise the use of other pharmacological measures, such as vasodilators. DiJretic therapy should be initiated with low doses otrurosemide (frusemide) [20 to 40 mg/day], with increased doses as needed, monitoring volume status by physical examination and laboratory data. Patients who are refractory to doses of furosemide of greater than 120 rug/day are treated with metolazone as adjunctive therapy. Meticulous monitoring of serum electrolytes is mandatory as potassium or magnesium supplementation may be necessary when these agents are used.
Anticoagulant Therapy
Patients with severe pulmonary hypertension are at risk for thrombotic events due to their sedentary lifestyle, venous insufficiency, dilated right heart chambers and sluggishpulmonary blood flow. Even a small pulmonary vascular obstruction by a thrombus can be life-threatening in a patient with a compromised pulmonary vascular bed which possesses little ability to dilate or recruit unused vessels. Indeed , patients with PPH frequently die suddenly, and fresh intrapulmonary clots may be found at postmortem. Thus, anticoagulation as a prophylaxis for thromboembolism seems justified~9 in patients with PPH. A retrospective study from the Mayo Clinic provided support for this concept -patients with PPH who were anticoagulated survived better than those who were not treated with anticoagulants (Fuster et al. 1984) .
The preferred approach to anticoagulants is to administer warfarin in doses sufficient to prolong the prothrombin time to approximately 1.3 to 1.5 times control. Patients should be advised about the risks .and-dangers of anticoagulation, and should avoid using nonsteroidal agents or any medication which could alter the effects of warfarin. Since right heart failure may impair hepatic function,monitoring .the anticoagulant effects of warfarin must be done frequently.
Adjusted-dose heparin, using doses which prolong the partial thromboplastin time to 1.3 to 1.5 times control , is a suitable alternative to warfarin, although its use is more cumbersome. This approach may be taken in patients who either have a greater risk for haemorrhagic events, such as prior episodes of hemoptysis, or who have had adverse effects with warfarin, such as alopecia. Lifethreatening haemoptysis, which can result from the spontaneous rupture of atherosclerotic vessels because of PPH, constitutes a contraindication to anticoagulation .
Vasodilators
The rationale for the use of vasodilato r agents to treat pulmonary hypertension is based on the premises that pulmonary vasoconstriction is present, to varying degrees, in this disease and that even small reductions in right ventricular afterload will produce substantial improvement in rightventricular output. This concept is supported by the pathological finding of medial hypertrophy of the muscular pulmonary arteries as an early and consistent feature of PPH (Wagenvoort 1960) . There is no selective pulmonary vasodilator agent, although 11 variety of systemic vasodilators have been demonstrated to produce pulmonary vascular effects in experimental and clinical conditions (table I) .
The goal of vasodilator therapy for PPH is to reduce pulmonary artery pressure and increase cardiac output without inducing symptomatic systemic hypotension. This effect may be achievable in up to one-third of patients who, by definition, have a significant potential for reversibility (Weir et al. 1989 ). reported that calcium channel blockers can produce sustained reductions in pulmonary artery pressure and regression of right ventricular hypertrophy in such patients.
In another approximately one-third of PPH patients, vasodilators will increase cardiac output without affecting pulmonary artery pressure (Weir et al. 1989 ). However, while exercise tolerance and right ventricular function may be improved in these patients, the long term effects on survival are unknown. Furthermore, whether this effect can be sustained for prolonged periods is unclear.
In the remaining one-third of patients, vasodilators either reduce systemic pressure without altering pulmonary artery pressure or cardiac output, or increase pulmonary artery pressure commensurate with an increased output. These patients are felt to have 'fixed' vascular disease and vasodilator therapy is contraindicated. Additionally, patients with pulmonary veno-occlusive disease may develop pulmonary oedema in response to vasodilator administration, presumably as a result of increasing pulmonary blood flow in the presence of persistent downstream vascular obstruction (Rubin There are no haemodynamic or demographic variables which can be used to predict vasoreactivity. I have cared for patients who have had symptoms for several years, suggestive of severe pulmonary vascular compromise, such as syncope, who manifested near complete reversibility when treated with vasodilators while others after a brief duration of symptoms had irreversible disease. This observation underscores the great variability in the course of this disease and emphasises the need to individualise the approach to therapy for each patient. The experience from the NIH Registry on PPH has suggested, however, that patients with right heart failure, defined as an elevated right atrial pressure, are at the greatest risk for adverse events when a long-acting, nontitratable vasodilator (such as an oral agent) is administered acutely (Weir et al. 1989 ).
Epoprosteno!
The use of intravenous infusions of epoprostenol (prostacyclin, prostaglandin 12) acutely during right heart catheterisation can determine the potential for reducing pulmonary vascular resistance (Rubin et al. 1982) . The advantages of epoprostenol are its potency as a pulmonary vasodilator, its titratability and its short half-life (approximately 3 minutes). Epoprostenol is ad- ministered in incremental doses from 2 to 12 ng/ kg/min, with monitoring of systemic and pulmonary haemodynamics, cardiac output and arterial saturation. The responses to epoprostenol have been useful in determining which patients may respond to oral therapy (Groves et al. 1985) . Epoprostenol is not commercially available in the United States at present; alternatives which may be suitable for testing acute reactivity include acetylcholine, nitroglycerin (glyceryl trinitrate) and prostaglandin EI. Jones and colleagues (1987) first reportedusing continuous intravenous infusions of epoprostenol in PPH, demonstrating sustained improvement in exercisetolerance with this aggressive approach. We recently demonstrated sustained improvements in haemodynamics in PPH' patients who were treated with long term continuous intravenous epoprostenol (Rubin et al. 1990 ). The drug is delivered by a portable infusion pump which is connected to a Hickman catheter inserted into the jugular or subclavian vein. Complications have generally been attributed to the drug delivery system and have included thrombosis or infection of the indwelling catheter, pump malfunction or interruption of the infusion for other reasons. Dose requirements tend to increase over time, suggesting tachyphylaxis, although several patients have maintained responses for periods extending beyond 2.5 years. This approach may be particularly useful as a bridge to transplantation in seriously ill patients in whom oral vasodilator therapy is either contraindicated or of no demonstrable benefit.
Calcium Antagonists
Patients who manifest a potentially beneficial response to epoprostenol, defined as either a substantial reduction in pulmonary artery pressure with no change or an increase in cardiac output, or an increase in cardiac output with no change or a decrease in pulmonary artery pressure, should be treated with oral calcium channel blockers. In general, sustained release nifedipine in doses of 30 to 120 mg/day, titrated gradually as the patient's vital signs, physical examination and symptoms dictate, may be used. In some patients, who either have a 41 resting tachycardia or develop unacceptable systemic hypotension with nifedipine, diltiazem 30 to 180mg 4 times daily can be given. The heart rate and the PR interval on the electrocardiogram should be monitored in patients receiving di1ti-azem since bradycardia and atrioventricular block may occur. Verapamil is not recommended for use in patients with PPH since it has a greater propensity to produce negative inotropic effects.
The major adverse effects of calcium channel blocker therapy in PPH patients are a reduction in cardiac output due to the negative inotropic effects, systemic hypotension and oedema due to salt and water retention . When oedema develops in a PPH patient on calcium channel blocker therapy, it is important to differentiate between the effects these agents have on renal salt and water reabsorption, and right heart failure due to negative inotropy. Vasodilators can also produce arterial hypoxaemia through 3 mechanisms: increasing blood flow to poorly ventilated lung units (decreasing V/o. relationships); increasing right-to-left shunting through a patient foramen ovale if a greater degree of systemic vasodilation than pulmonary vasodilation is produced ; and decreasing mixed venous oxygen content if cardiac output actually falls. The first scenario occurs more commonly in patients with pulmonary hypertension secondary to underlying parenchymal lung disease (Melot et al, 1983) , while right-to-left shunting through a patent foramen ovale occurs only in more severe forms of pulmonary hypertension. A similar phenomenon may occur in patients with Eisenmenger's complex who are given vasodilators.
Other Drugs
Nitrates, either oral or topical, have been used to treat some patients with PPH, although the experience .with these agents to date is limited. Direct-acting agents, such as hydralazine and diazoxide, may be useful in select patients with marked reactivity, but systemic hypotension has limited their utility. Results with the angiotensin converting enzyme inhibitors have been disappointing and their use is not recommended (Weir et al. 1989 ).
Conslcer ncreasmq cosage 0 oral or topicalmedication. or consider continuous Intravenous epoprostenol 
Transplantation
Combined heart-lung transplantations have been performed successfully on patients with PPH for nearly a decade (Reitz et al. 1982 ). The major limDrugs 43 (1) 1992 itations to the widespread utility of transplantation include the number of centres with the expertise to perform the procedure and care for the patients, and the availability of suitable donor organs. Additional problems have included the high incidence (25 to 40%) of bronchiolitis obliterans in transplanted lungs, organ rejection and opportunistic infections.
Recently, single lung transplantations were performed successfully in several patients with PPH. Pulmonary artery pressure decreased and right ventricular function improved dramatically in the few patients evaluated to date. Although rejection, . , infection and bronchiolitis may occur in single lung transplantations, it is likely that there should be a greater availability of suitable donor organs for single lung transplantations than for combined heart-lung transplantations. Thus, single lung transplantation may be the surgical procedure of choice for patients in whom right heart function is not irreversibly impaired.
The timing of transplantation is controversial and dependent, in part, on the individual patient's wishes. In general, I advocate consideration for transplantation for patients in New York Heart Association Functional Class III or IV who are refractory to medical management or whose condition is deteriorating despite aggressive medical management.
Prognosis
The prognosis ofPPH is highly variable and the influence of medical or surgical therapy for this disease has not been assessed in prospective, long term studies. In general, survival appears to be correlated with the status of right heart function as assessed by either cardiac output, pulmonary vascular resistance, right atrial pressure , or mixed venous oxygen saturation. Patients with signs of right heart failure have a mean survival of approximately 6 to 12 months, while patients with minimal symptoms and preserved right heart function may live for several years.
Conclusions and Recommendations
The management ofPPH ( fig. 1 ) is complex and requires meticulous monitoring of the patient's clinical status using invasive and noninvasive modalities. Anticoagulation is recommended in all patients unless contraindicated, and some patients may benefit from low-flow oxygen therapy partieularly with activity. Diuretics should be used cautiously when signs of right heart failure are.present. Vasodilator therapy should be instituted only when there is haemodynamic evidence of benefit. Patients who are unresponsive to conventional vasodilator therapy should be evaluated for more aggressive approaches, such as continuous intravenous epoprostenol or transplantation.
